

Ibutilast produces anti-allodynic effects at the persistent phase of peripheral or central neuropathic pain in rats: different inhibitory mechanism on spinal microglia from minocycline and propentofylline

Masahide Fujita, Ryuta Tamano, Sosuke Yoneda, Shigeki Omachi, Erika Yogo, Masatomo Rokushima, Shunji Shinohara, Gaku Sakaguchi, Minoru Hasegawa, Toshiyuki Asaki



PII: S0014-2999(18)30336-4  
DOI: <https://doi.org/10.1016/j.ejphar.2018.06.009>  
Reference: EJP71839

To appear in: *European Journal of Pharmacology*

Received date: 4 July 2017

Revised date: 6 June 2018

Accepted date: 6 June 2018

Cite this article as: Masahide Fujita, Ryuta Tamano, Sosuke Yoneda, Shigeki Omachi, Erika Yogo, Masatomo Rokushima, Shunji Shinohara, Gaku Sakaguchi, Minoru Hasegawa and Toshiyuki Asaki, Ibutilast produces anti-allodynic effects at the persistent phase of peripheral or central neuropathic pain in rats: different inhibitory mechanism on spinal microglia from minocycline and propentofylline, *European Journal of Pharmacology*, <https://doi.org/10.1016/j.ejphar.2018.06.009>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting galley proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Ibutilast produces anti-allodynic effects at the persistent phase of peripheral or central neuropathic pain in rats: different inhibitory mechanism on spinal microglia from minocycline and propentofylline

Masahide Fujita<sup>1\*</sup>, Ryuta Tamano<sup>2</sup>, Sosuke Yoneda<sup>2</sup>, Shigeki Omachi<sup>3</sup>, Erika Yogo<sup>4</sup>, Masatomo Rokushima<sup>4</sup>, Shunji Shinohara<sup>5</sup>, Gaku Sakaguchi<sup>6</sup>, Minoru Hasegawa<sup>7</sup>, Toshiyuki Asaki<sup>2</sup>

<sup>1</sup>Department of Neuroscience, Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd., Osaka, Japan.

<sup>2</sup>Department of Neuroscience, Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd., Osaka, Japan.

<sup>3</sup>Medical Affairs Department, Shionogi & Co., Ltd., Osaka, Japan.

<sup>4</sup>Department of Drug Discovery Technologies, Drug Discovery & Disease Research Laboratory, Shionogi & Co., Ltd., Osaka, Japan.

<sup>5</sup>Drug Efficacy Evaluation III, Technology for Animal Models, Shionogi Techno Advance Research Co. Ltd., Toyonaka, Osaka, Japan

Download English Version:

<https://daneshyari.com/en/article/8528960>

Download Persian Version:

<https://daneshyari.com/article/8528960>

[Daneshyari.com](https://daneshyari.com)